
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New Orleans - When it comes to understanding dandruff, two top researchers at Procter & Gamble are successfully getting to the root of the nasty scalp condition that affects more than half of the global population. Innovative research in P&G's lab has yielded some surprising new data about a type of fungus that grows on the human scalp. The study findings point to new causes of dandruff and lay the groundwork for new cures.